Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Royal Children's Hospital · University of Toronto · +20 more institutions
Abstract
Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy. Download a PDF of the Research Summary. In this phase 2 trial, patients with pediatric low-grade glioma with BRAF V600 mutations who were scheduled to receive first-line therapy were randomly assigned in a 2:1 ratio to receive dabrafenib plus trametinib or standard chemotherapy (carboplatin plus vincristine). The primary…
Citation impact
- FWCI
- 69.71
- Percentile
- 100%
- References
- 33
Authors
18- ÉBÉric BouffetCorresponding
Royal Children's Hospital, University of Toronto, Hospital for Sick Children, Murdoch Children's Research Institute
- JRJordan R. Hansford
Royal Children's Hospital, The University of Adelaide
- MLMaria Luisa Garrè
Royal Children's Hospital, Istituto Giannina Gaslini
- JHJunichi Hara
Royal Children's Hospital, Osaka City General Hospital
- APAshley Plant
Lurie Children's Hospital, Royal Children's Hospital
Topics & keywords
- Dabrafenib
- Trametinib
- Glioma
- Medicine
- Oncology
- Internal medicine
- Cancer research
- Biology
- Good health and well-being